1.
On the Construction of China s Medicine Evaluation Advisory Committee Systems;
论我国药品审评咨询委员会制度的构建
2.
Discussion on the Revelatory Effects of Canada s CDR System to China;
加拿大的共同药品审评(CDR)制度及对我国的启示
3.
Problem analysis of residual solvents control in drug evaluation
药品审评过程中残留溶剂检查常见问题分析
4.
Analysis and Inspiration of FDA CDER Sharing the Public Information Disclosure;
美国食品药品监督管理局药品审评和研究中心公众共享信息披露的分析和启示
5.
Design and Actualization of the Information System for Drug Evaluation Based on Knowledge Management;
基于知识管理的药品审评信息系统的设计及实施
6.
National Committee on the assessment of protected traditional Chinese medicinal products
国家中药品种保护审评委员会
7.
The Necessity of GLP Implementation From Point View of Drug Technical Evaluation;
从药品技术审评的角度看GLP实施的必要性
8.
GSP Interior Appraisal of Request,Procedure and Key in the Drugs Management Enterprise
药品经营企业GSP内部评审的要求、程序及重点
9.
Guarantee Role of Information Technology in the Drug Technological Evaluation Process
信息技术对我国药品技术审评工作的保障作用
10.
FDA s Question-based Review: A Quality Assessment System for Generic Drugs;
FDA的仿制药品上市申请“问答式审评”质量评估体系简介
11.
Analysis of the Canadian Common Drug Review and Its Implication for Chinese Drug Review;
对加拿大药品统一审评的分析及其对我国的启示
12.
An Analysis of FDA Botanical Drug Policy in the Context of VeregenTM Labeling;
从VEREGEN~(TM)的商品说明书内容看FDA植物新药评审的思路与要求
13.
Discussion on Definition of Drug From the Phenomenon of Health Food Imitating as Drug
从保健食品冒充药品现象来审视“药品”的定义
14.
Review of requirements related to the product
与产品有关要求的评审
15.
CMC review of veregen and its enlightenment to the quality control of new Chinese herbal medicine
Veregen的药学审评对中药新药质量控制研究的启示
16.
Clinical Institute Narcotic Assessment (CINA scale)
临床麻醉药品评估量表
17.
The Application Research of Pharmacoeconomic Evaluation in New Chinese Traditional Patent Medicine Pre-market Evaluation
药物经济学评价在中成药新药上市评审中的应用研究
18.
The Basic Bio-evaluation Principles for Pesticide Registration;
农药登记的生物学资料评审基本原则